MLTX
MoonLake Immunotherapeutics
NASDAQ · Healthcare · Biotechnology · CH
$9.75
+2.09%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$9.57
From 52W high−56.00%
Volume906379.00
Market cap$829.79M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$9.57
From 52W high
−56.00%
Volume
906379.00
Market cap
$829.79M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
P/E (TTM)
—
RSI (14)
25.4
MomentumView details →
1D Return
+2.09%
YTD Return
−26.02%
SummaryUpdated Jun 1, 2026
MoonLake Immunotherapeutics (NASDAQ:MLTX) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Zug, Switzerland. The company went public in October 2020 and focuses on developing innovative therapies for inflammatory conditions. MoonLake is currently advancing its lead candidate, Sonelokimab, through multiple Phase II clinical trials targeting various autoimmune and inflammatory diseases.
Similar companies
Latest newsMore news →
MoonLake Immunotherapeutics announced positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, meeting all clinical endpoints at Week 16, and reported second quarter 2026 financial results with $537.0 million in cash and cash equivalents as of the end of the quarter.71d agoMoonLake Immunotherapeutics priced an upsized $200 million public offering of 9,000,000 Class A ordinary shares and pre-funded warrants for up to 1,000,000 Class A ordinary shares.118d agoMoonLake Immunotherapeutics signed a Master Commercial Supply Agreement and a Capacity Agreement with Vetter Pharma International GmbH for the manufacture of pre-filled application systems and capacity reservation.141d ago